{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:46:49Z","timestamp":1786981609946,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA233184"],"award-info":[{"award-number":["UG1CA233184"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["U10CA180794"],"award-info":[{"award-number":["U10CA180794"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189828"],"award-info":[{"award-number":["UG1CA189828"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["U10CA180820"],"award-info":[{"award-number":["U10CA180820"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189974"],"award-info":[{"award-number":["UG1CA189974"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189860"],"award-info":[{"award-number":["UG1CA189860"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189863"],"award-info":[{"award-number":["UG1CA189863"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189953"],"award-info":[{"award-number":["UG1CA189953"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189956"],"award-info":[{"award-number":["UG1CA189956"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189957"],"award-info":[{"award-number":["UG1CA189957"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA233180"],"award-info":[{"award-number":["UG1CA233180"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA233196"],"award-info":[{"award-number":["UG1CA233196"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017788","name":"ECOG-ACRIN Cancer Research Group","doi-asserted-by":"publisher","award":["UG1CA189858"],"award-info":[{"award-number":["UG1CA189858"]}],"id":[{"id":"10.13039\/100017788","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["R25CA122061"],"award-info":[{"award-number":["R25CA122061"]}]},{"name":"National Cancer Institute","award":["P30 CA1777558"],"award-info":[{"award-number":["P30 CA1777558"]}]},{"name":"National Cancer Institute","award":["L30CA231709"],"award-info":[{"award-number":["L30CA231709"]}]},{"name":"National Center for Clinical and Translational Science","award":["2KL2TR001996-05A1"],"award-info":[{"award-number":["2KL2TR001996-05A1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11136-022-03226-8","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T03:02:38Z","timestamp":1661569358000},"page":"183-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient-reported tolerability of adjuvant ipilimumab (3 or 10\u00a0mg\/kg) versus high-dose interferon alfa-2b for resected high-risk stage III\u2013IV melanoma in phase III trial E1609"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-6520","authenticated-orcid":false,"given":"Laurie E.","family":"McLouth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma N.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas T.","family":"Amatruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan D.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Nakhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa R.","family":"Chandana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Marinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"issue":"1","key":"3226_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"14","key":"3226_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., \u2026 Larkin, J. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14), 1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"3226_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., ChiarionSileni, V., Schachter, J., Garbe, C., Bondarenko, I., Gogas, H., Mandala, M., Haanen, J., Lebbe, C., Mackiewicz, A., Rutkowski, P., Nathan, P. D., Ribas, A., Davies, M. A., \u2026 Long, G. V. (2019). Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New England Journal of Medicine, 381(7), 626\u2013636. https:\/\/doi.org\/10.1056\/NEJMoa1904059","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"3226_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F., for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. (2017). Melanoma staging: Evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians, 67(6), 472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"6","key":"3226_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.19.01381","volume":"38","author":"AA Tarhini","year":"2020","unstructured":"Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., Koon, H. B., Lawrence, D. P., Kendra, K. L., Minor, D. R., Lee, C. B., Albertini, M. R., Flaherty, L. E., Petrella, T. M., Streicher, H., \u2026 Kirkwood, J. M. (2020). Phase iii study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North american intergroup e1609. Journal of Clinical Oncology, 38(6), 567\u2013575. https:\/\/doi.org\/10.1200\/JCO.19.01381","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"3226_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"JM Kirkwood","year":"1996","unstructured":"Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684. Journal of Clinical Oncology, 14(1), 7\u201317. https:\/\/doi.org\/10.1200\/JCO.1996.14.1.7","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"3226_CR7","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","volume":"18","author":"JM Kirkwood","year":"2000","unstructured":"Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial e1690\/s9111\/c9190. Journal of Clinical Oncology, 18(12), 2444\u20132458. https:\/\/doi.org\/10.1200\/JCO.2000.18.12.2444","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"3226_CR8","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","volume":"19","author":"JM Kirkwood","year":"2001","unstructured":"Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the gm2-klh\/qs-21 vaccine in patients with resected stage iib-iii melanoma: Results of intergroup trial e1694\/s9512\/c509801. Journal of Clinical Oncology, 19(9), 2370\u20132380. https:\/\/doi.org\/10.1200\/JCO.2001.19.9.2370","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"3226_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2001.19.5.1430","volume":"19","author":"JM Kirkwood","year":"2001","unstructured":"Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., & Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to gm2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase ii trial e2696. Journal of Clinical Oncology, 19(5), 1430\u20131436. https:\/\/doi.org\/10.1200\/JCO.2001.19.5.1430","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"3226_CR10","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., Siegel, J., & O\u2019Day, S. J. (2009). A randomized, double-blind, placebo-controlled, phase ii study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage iii or iv melanoma. Clinical Cancer Research, 15(17), 5591\u20135598. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1024","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"3226_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O'Day","year":"2010","unstructured":"O\u2019Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., Verschraegen, C., Humphrey, R., Ibrahim, R., de Pril, V., Hoos, A., & Wolchok, J. D. (2010). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase ii study. Annals of Oncology, 21(8), 1712\u20131717. https:\/\/doi.org\/10.1093\/annonc\/mdq013","journal-title":"Annals of Oncology"},{"issue":"8","key":"3226_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S., O\u2019Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., \u2026 Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"New England Journal of Medicine"},{"key":"3226_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-79","author":"K Webster","year":"2003","unstructured":"Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (facit) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes. https:\/\/doi.org\/10.1186\/1477-7525-1-79","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"3226_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost, K. J., & Eton, D. T. (2005). Combining distribution- and anchor-based approaches to determine minimally important differences: The facit experience. Evaluation and the Health Professions, 28(2), 172\u2013191. https:\/\/doi.org\/10.1177\/0163278705275340","journal-title":"Evaluation and the Health Professions"},{"issue":"1","key":"3226_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11136-004-1694-x","volume":"14","author":"AG Paterson","year":"2005","unstructured":"Paterson, A. G., Trask, P. C., Wagner, L. I., Esper, P., & Redman, B. (2005). Validation of the fact-brm with interferon-alpha treated melanoma patients. Quality of Life Research, 14(1), 133\u2013139. https:\/\/doi.org\/10.1007\/s11136-004-1694-x","journal-title":"Quality of Life Research"},{"issue":"1","key":"3226_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:QURE.0000015297.91158.01","volume":"13","author":"J Bacik","year":"2004","unstructured":"Bacik, J., Mazumdar, M., Murphy, B. A., Fairclough, D. L., Eremenco, S., Mariani, T., Motzer, R. J., & Cella, D. (2004). The functional assessment of cancer therapy-brm (fact-brm): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of Life Research, 13(1), 137\u2013154. https:\/\/doi.org\/10.1023\/B:QURE.0000015297.91158.01","journal-title":"Quality of Life Research"},{"issue":"3","key":"3226_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-018-4713-2","volume":"169","author":"LI Wagner","year":"2018","unstructured":"Wagner, L. I., Zhao, F., Goss, P. E., Chapman, J. W., Shepherd, L. E., Whelan, T. J., Mattar, B. I., Bufill, J. A., Schultz, W. C., LaFrancis, I. E., Nagargoje, G. G., Vemuri, R., Nikcevich, D. A., Sledge, G. W., & Cella, D. (2018). Patient-reported predictors of early treatment discontinuation: Treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on ncic clinical trials group (cctg) ma.27 (e1z03). Breast Cancer Research and Treatment, 169(3), 537\u2013548. https:\/\/doi.org\/10.1007\/s10549-018-4713-2","journal-title":"Breast Cancer Research and Treatment"},{"issue":"5","key":"3226_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/cncr.31133","volume":"124","author":"TP Pearman","year":"2018","unstructured":"Pearman, T. P., Beaumont, J. L., Mroczek, D., O\u2019Connor, M., & Cella, D. (2018). Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer, 124(5), 991\u2013997. https:\/\/doi.org\/10.1002\/cncr.31133","journal-title":"Cancer"},{"issue":"2","key":"3226_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1524-4733.2005.08202.x","volume":"8","author":"KJ Yost","year":"2005","unstructured":"Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (2005). Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (fact-brm) instrument. Value in Health, 8(2), 117\u2013127. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.08202.x","journal-title":"Value in Health"},{"issue":"33","key":"3226_CR20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., \u2026 Robert, C. (2020). Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage iii melanoma: Updated results from the eortc 1325-mg\/keynote-054 trial. Journal of Clinical Oncology, 38(33), 3925\u20133936. https:\/\/doi.org\/10.1200\/JCO.20.02110","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"3226_CR21","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1007\/s00520-022-06802-3","volume":"30","author":"P Griffiths","year":"2022","unstructured":"Griffiths, P., Peipert, J. D., Leith, A., Rider, A., Morgan, L., Cella, D., & Cocks, K. (2022). Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Supportive Care in Cancer, 30(4), 3613\u20133623. https:\/\/doi.org\/10.1007\/s00520-022-06802-3","journal-title":"Supportive Care in Cancer"},{"issue":"15_suppl","key":"3226_CR22","doi-asserted-by":"publisher","first-page":"e19132","DOI":"10.1200\/JCO.2020.38.15_suppl.e19132","volume":"38","author":"F Zhao","year":"2020","unstructured":"Zhao, F., Peipert, J., Lee, J.-W., Hong, F., Ip, E., Gareen, I. F., O\u2019Connell, N., Carlos, R., Mayer, I. A., Miller, K., Partridge, A. H., Shanafelt, T. D., Stewart, A. K., Tarhini, A. A., Thomas, M. L., Weiss, M., Sparano, J. A., Cella, D., Gray, R. J., & Wagner, L. I. (2020). Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials. Journal of Clinical Oncology, 38(15_suppl), e19132\u2013e19132. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e19132","journal-title":"Journal of Clinical Oncology"},{"issue":"SUPPL 1","key":"3226_CR23","first-page":"S51","volume":"30","author":"J Peipert","year":"2021","unstructured":"Peipert, J., Zhao, F. M., Lee, J. W., Hong, F., Shen, S. E., Ip, E., O\u2019Connell, N., Graham, N., Smith, M. L., Gareen, I., Carlos, R., Obeng-Gyasi, S., Kumar, S. K., Miller, K., Partridge, A., Shanafelt, T., Sparano, J. A., Stewart, K., Tarhini, A., \u2026 Wagner, L. I. (2021). Change in a single-item indicator of treatment tolerability in cancer is associated with early treatment discontinuation. Quality of Life Research, 30(SUPPL 1), S51\u2013S51.","journal-title":"Quality of Life Research"},{"issue":"34","key":"3226_CR24","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","volume":"30","author":"E Basch","year":"2012","unstructured":"Basch, E., Abernethy, A. P., Mullins, C. D., Reeve, B. B., Smith, M. L., Coons, S. J., Sloan, J., Wenzel, K., Chauhan, C., Eppard, W., Frank, E. S., Lipscomb, J., Raymond, S. A., Spencer, M., & Tunis, S. (2012). Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. Journal of Clinical Oncology, 30(34), 4249\u20134255. https:\/\/doi.org\/10.1200\/JCO.2012.42.5967","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"3226_CR25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/cncr.32692","volume":"126","author":"AR Hansen","year":"2020","unstructured":"Hansen, A. R., Ala-Leppilampi, K., McKillop, C., Siu, L. L., Bedard, P. L., Abdul Razak, A. R., Spreafico, A., Sridhar, S. S., Leighl, N., Butler, M. O., Hogg, D., Sacher, A., Oza, A. M., Al-Agha, R., Maurice, C., Chan, C. T., Shapera, S., Feld, J. J., Nisenbaum, R., \u2026 Parsons, J. (2020). Development of the functional assessment of cancer therapy-immune checkpoint modulator (fact-icm): A toxicity subscale to measure quality of life in patients with cancer who are treated with icms. Cancer, 126(7), 1550\u20131558. https:\/\/doi.org\/10.1002\/cncr.32692","journal-title":"Cancer"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-022-03226-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03226-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T10:44:24Z","timestamp":1673606664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-022-03226-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3226"],"URL":"https:\/\/doi.org\/10.1007\/s11136-022-03226-8","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,27]]},"assertion":[{"value":"2 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>FSH<\/i>: Stock and Other Ownership Interests: Apricity; Torque Consulting or Advisory Role: Merck Sharp & Dohme, Novartis, Genentech\/Roche, EMD Serono, Sanofi, Bayer, Aduro Biotech, Pfizer, Verastem, Bristol-Myers Squibb, Takeda Pharmaceuticals, Surface, Compass Therapeutics, Partners Therapeutics, Pionyr, 7Hills Pharma, Torque, and Rheos; Research Funding: Bristol-Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Genentech\/Roche (Inst), and Novartis (Inst) Patents; Royalties and Other Intellectual Property: Patent pending as per institutional policy; patent-pending royalties received on MICA-related disorder application to institution per institutional IP policy; angiopoietin-2 biomarkers predictive of anti-immune checkpoint response (Inst); compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms; and methods of using pembrolizumab and trebananib (Inst); Travel, Accommodations, and Expenses: Novartis, Bristol-Myers Squibb; Other Relationship: Bristol-Myers Squibb and Genentech\/Roche; <i>GIC<\/i>: Stock and Other Ownership Interests: Nymox, Celgene, AbbVie; Honoraria: Amgen; <i>SJL<\/i>: Stock and Other Ownership Interests: NantKwest (I); Consulting or Advisory Role: Roche\/Genentech; <i>VKJ<\/i>: Consulting or Advisory Role: Merck\/Schering-Plough, Novartis, Bristol-Myers Squibb, Array BioPharma, Genentech\/Roche, Pfizer, Polynoma, Regeneron, and Replimune; <i>JMK<\/i>: Consulting or Advisory Role: Bristol-Myers Squibb, Novartis, Array BioPharma, Immunocore, Iovance, Elsevier, Checkmate Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Immunocore (Inst), and Merck (Inst); Research Funding: Merck (Inst), Prometheus Laboratories (Inst), and Immunocore (Inst); <i>AAT<\/i>: Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Genentech\/Roche, Incyte, Newlink Genetics, Array BioPharma, Novartis, OncoSec, HUYA Bioscience International, Immunocore, Pfizer\/EMD Serono, Sanofi\/Regeneron, and BioNTech; Research Funding: Incyte (Inst), Prometheus Laboratories (Inst), Bristol-Myers Squibb (Inst), Amgen (Inst), Incyte (Inst), Novartis (Inst), GreenPeptide (Inst), and Merck (Inst). No other potential conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Institutional Review Boards at each registering institution. Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}